Barclays PLC Grows Stock Position in Surgery Partners, Inc. (NASDAQ:SGRY)

Barclays PLC boosted its holdings in shares of Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 9.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 141,094 shares of the company's stock after buying an additional 11,961 shares during the quarter. Barclays PLC owned 0.11% of Surgery Partners worth $2,987,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Franklin Resources Inc. boosted its holdings in Surgery Partners by 19.5% in the third quarter. Franklin Resources Inc. now owns 21,324 shares of the company's stock valued at $677,000 after purchasing an additional 3,487 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Surgery Partners in the third quarter worth about $1,469,000. JPMorgan Chase & Co. grew its holdings in Surgery Partners by 3.0% during the third quarter. JPMorgan Chase & Co. now owns 189,436 shares of the company's stock worth $6,107,000 after acquiring an additional 5,551 shares during the period. Harbor Capital Advisors Inc. raised its position in Surgery Partners by 25.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 67,443 shares of the company's stock valued at $1,428,000 after acquiring an additional 13,588 shares in the last quarter. Finally, Inspire Investing LLC lifted its holdings in Surgery Partners by 47.5% in the fourth quarter. Inspire Investing LLC now owns 19,034 shares of the company's stock valued at $403,000 after acquiring an additional 6,131 shares during the period.

Surgery Partners Price Performance

Shares of Surgery Partners stock traded up $0.65 during mid-day trading on Friday, reaching $23.08. 554,747 shares of the stock traded hands, compared to its average volume of 1,100,705. The stock has a market capitalization of $2.95 billion, a PE ratio of -48.08, a PEG ratio of 19.21 and a beta of 2.40. The business has a 50-day moving average of $22.80 and a 200 day moving average of $23.86. Surgery Partners, Inc. has a fifty-two week low of $19.50 and a fifty-two week high of $33.97. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.99.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.38 by $0.01. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $828.09 million. On average, analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current year.

Insider Activity at Surgery Partners

In other Surgery Partners news, CFO David T. Doherty sold 13,641 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.61, for a total transaction of $349,346.01. Following the transaction, the chief financial officer now owns 108,862 shares of the company's stock, valued at approximately $2,787,955.82. The trade was a 11.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Marissa Brittenham sold 3,156 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $24.09, for a total value of $76,028.04. Following the completion of the sale, the insider now directly owns 63,408 shares of the company's stock, valued at $1,527,498.72. This trade represents a 4.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 106,622 shares of company stock valued at $2,717,860. Corporate insiders own 2.30% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Benchmark reiterated a "buy" rating and issued a $35.00 target price on shares of Surgery Partners in a research note on Monday, April 21st. Macquarie decreased their price objective on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating for the company in a research report on Tuesday, March 11th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $35.00 target price on shares of Surgery Partners in a research report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $34.75.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.